Hookipa Pharma — Corporate Update (December 2020)
22 slides from Hookipa Pharma's corporate update, Dec 7, 2020
Slide 1: HB-200 Arenavirus-based Therapeutics for HPV16+ Cancers
1 HOOKIPA Pharma HB - 200 Arenavirus - based Therapeutics for HPV16+ Cancers December 7, 2020
Slide 2: Forward-looking statements
2 HOOKIPA Pharma This Presentation includes forward - looking statements . All statements other than statements of historical facts contained in these materials or elsewhere, including statements regarding (i) the success, cost, results and timing of HOOKIPA’s product development activities and clin
Slide 3: HB-201 Monotherapy Phase 1 Data Shows Promising Anti-Tumor Activity and Favorable Tolerability
3 HOOKIPA Pharma HB - 201 Monotherapy Phase 1 Data Shows Promising Anti - Tumor Activity and Favorable Tolerability as Treatment for Advanced HPV16 + Cancers • HB - 201 monotherapy, a replicating single vector (LCMV 1 ) therapy, in advanced metastatic patients, demonstrated 2 : • Favorable tolerabil
Slide 4: Engineered Arenaviruses Create Outstanding T Cell Responses
4 HOOKIPA Pharma Preclinically, Our Engineered Arenaviruses Create Outstanding T Cell Responses ( Up to >50% of CD8 + T Cells) Against Tumor Self Antigens 0 2 4 6 81010 20 30 40 50 60 70 80 % Tumor Antigen Specific CD8+ (P1A; cancer testis antigen) Replicating Single Vector Non-Replicating Single Ve
Slide 5: Dose-Dependent Correlation Between T Cell Responses and Tumor Control
5 HOOKIPA Pharma Preclinical Studies with Engineered Arenaviruses Showed a Dose - Dependent Correlation Between T Cell Responses and Tumor Control 0 2 4 6 81010 20 30 40 50 60 70 80 % Tumor Antigen Specific CD8+ (P1A; cancer testis antigen) Replicating Single Vector Non-Replicating Single Vector Rep
Slide 6: Focus on Interim Phase 1 Results of HB-201
6 HOOKIPA Pharma Today the Focus Will Be on the Interim Phase 1 Results of HB - 201, a Replicating Single Vector Therapy Technology of H O O KIPA Programs HB - 101 CMV HB - 201 HPV + monotherapy HB - 202/201 HPV + HB - 300 Prostate 0 2 4 6 81010 20 30 40 50 60 70 80 % Tumor Antigen Specific CD8+ (P1
Slide 7: HB-201 and HB-202 Express E7/E6 Antigens with Different Replicating Arenaviral Vectors
7 HOOKIPA Pharma • What: Replicating 2 Vector (PICV + LCMV) encoding E7/E6 antigen • Approach: Potential best - in - class therapeutic for metastatic HPV16 + cancers o Expected to deliver ~10x greater level of antigen - specific T cells to the tumor relative to HB - 201 monotherapy, based on preclin
Slide 8: Ongoing Phase 1 Trial: Dose Escalation of HB-201 Monotherapy
8 HOOKIPA Pharma When open, Group 4 will utilize the alternating vector therapy of HB - 202 & HB - 201 in HPV16+ cancers accessible for intra - tumoral injection. Study milestones • First patient dosed on HB - 201: December 2019 • First patient dosed on HB - 202/HB - 201: October 2020 Group Summarie
Slide 9: Heavily Pre-treated Patients with Metastatic HPV16+ Tumors Enrolled
9 HOOKIPA Pharma Patients Evaluable for First Scan 15 HNSCC Patients Evaluable for First Scan 11 Patients on HB - 201 Monotherapy 22 Footnote from slide 12 1 Heavily Pre - treated Patients with Metastatic HPV16+ Tumors Enrolled into Ongoing Phase 1 Trial 4 Other HPV16+ Patients Evaluable for First S
Slide 10: HB-201 Observed to Have Favorable Tolerability Profile
10 HOOKIPA Pharma Patients with reported AEs Number of patients reporting / Number of patients treated (%) Treated patients with reported AEs 15 / 22 (68%) Patients with reported TRAEs 9 / 22 (41%) Patients with reported TRAEs related to IV HB - 201 1 8 / 22 (36%) Patients with reported TRAEs relate
Slide 11: HB-201 Monotherapy Demonstrating Promising Efficacy in 3L+ HPV16+ Patients
11 HOOKIPA Pharma HB - 201 Monotherapy Demonstrating Promising Efficacy in 3L+ HPV16 + Patients Secondary Endpoint: Efficacy by RECIST 1.1 3 rd + Line Metastatic HNSCC* Patients (N=11): All progressed on prior PD1 inhibitor • 1 Pt with Unconfirmed Complete Response • 1 Pt with Unconfirmed Partial Re
Slide 12: HB-201 Monotherapy Efficacy Data: Time on Study and Target Lesion Response
12 HOOKIPA Pharma HB - 201 Monotherapy Efficacy Data : Time on Study and Target Lesion Response For All Treated Patients (N=22) * Not evaluable (5 ongoing but too early for scans: Pt 22, 21,18,17, 3, 1 WOC before 1st scan: Pt 6, 1 judged to be CP before 1s t scan: Pt 4. a Not yet entered into EDC. C
Slide 13: Target Lesion Change from Baseline by Scan
13 HOOKIPA Pharma a Not yet entered into EDC. Definitions : iuCR : unconfirmed immune complete response ( iRECIST ); uPR : unconfirmed partial response (RECIST v1.1); SD : stable disease (RECIST v1.1); iSD : immune stable disease (RECIST v1.1); PD : progressive disease (RECIST v1.1); iuPD : immune u
Slide 14: Efficacy Data for Evaluable Patients with HNSCC
14 HOOKIPA Pharma 0 1 2 3 4 -100 -80 -60 -40 -20 0 20 40 60 80 100 C h a n g e o f t a r g e t l e s i o n f r o m b a s e l i n e ( % ) B a s e l i n e 1 s t s c a n 2 n d s c a n 3 r d s c a n 4 t h s c a n Dose Level 1 Group 1 HPV16+ HNSCC IV-IV Dose Level 1 Group 2 HPV16+ Cancers IT-IV Dose Leve
Slide 15: HB-201 Demonstrating Promising Progression Free Survival
15 HOOKIPA Pharma HB - 201 Demonstrating Promising Progression Free Survival Median PFS in All Evaluable HPV16 + Patient Cohort ( HNSCC, Cervical, Anal, Vaginal, N=15) is also currently 72 days and is ongoing. Median PFS currently 72 days, ongoing Median Progression Free Survival (PFS) in Evaluable
Slide 16: Patient Profile #1: HNSCC with Unconfirmed Complete Response
16 HOOKIPA Pharma Patient Profile #1: 68 - Year - Old Male with HNSCC & Unconfirmed Complete Response (Dose Level 1 IV - IV) C, cycle; CPI, checkpoint inhibitor; D, day; FU, fluorouracil; XRT, radiation therapy. Prior treatments: 4 prior lines of therapy Cisplatin + XRT Ź Carboplatin/5 - FU/ pembrol
Slide 17: Patient Profile #2: HNSCC with Unconfirmed Partial Response
17 HOOKIPA Pharma Prior treatments: 3 prior lines of therapy Cisplatin + XRT Ź Carboplatin/paclitaxel/cetuximab Ź Pembrolizumab (21 days since last CPI) Results: Rapid disease stabilization followed by unconfirmed PR 20% reduction by C3D1 Ź 41% reduction by C5D1 Status: Patient remains on study afte
Slide 18: Patient Profile #3: HNSCC with Progression, Then Stable Disease
18 HOOKIPA Pharma Prior treatments: 2 prior lines of therapy Durvalumab / monalizumab /cetuximab Ź Pembrolizumab/carboplatin/5 - FU (Keynote - 048; 42 days since last CPI) Results: PD at first scan followed by disease stabilization Status: Patient is currently on study after 91 days Baseline 1 st Sc
Slide 19: Patient Profile #4: HNSCC with Stable Disease in Combination With Pembrolizumab
19 HOOKIPA Pharma Prior treatments: 3 prior lines of therapy Pembrolizumab/carboplatin/5 - FU Ź Cetuximab Ź Pembrolizumab/carboplatin (POD on treatment 38 days since last CPI) Results: Potential target lesion response in combination with pembrolizumab after progression on 2 prior rounds of pembroliz
Slide 20: Initial Phase 1 Cohorts: Promising Interim Data
20 HOOKIPA Pharma Initial Phase 1 Cohorts: Promising Interim Data o Favorable tolerability o Shows evidence of efficacy in a heavily pretreated patients with HPV16 + cancers • 18% unconfirmed response rate and 72% disease control rate in 11 evaluable HNSCC patients • 1 patient with an unconfirmed co
Slide 21: Initial Replicating Vector Clinical Data in HPV16+ Cancers Due in Mid-2021
21 HOOKIPA Pharma Initial Replicating 2 Vector Clinical Data in HPV16 + Cancers Due in Mid - 2021 Technology of H O O KIPA Programs HB - 101 CMV HB - 201 HPV+ monotherapy HB - 202/201 HPV + HB - 300 Prostate 0 2 4 6 81010 20 30 40 50 60 70 80 % Tumor Antigen Specific CD8+ (P1A; cancer testis antigen
Slide 22: HOOKIPA
=») HOOKIPA